Analyst Ratings For NASDAQ:BLUE – bluebird bio (NASDAQ:BLUE)
Today, Cantor Fitzgerald reiterated its Sell rating on NASDAQ:BLUE – bluebird bio (NASDAQ:BLUE) with a price target of $122.00.
Some recent analyst ratings include
- 5/10/2018-Cantor Fitzgerald Reiterated Rating of Sell.
- 5/7/2018-Sanford C. Bernstein Reiterated Rating of Market Perform.
- 5/3/2018-BTIG Research Reiterated Rating of Buy.
- 3/28/2018-Canaccord Genuity Reiterated Rating of Buy.
- On 5/2/2018 David Davidson, Insider, sold 13,000 with an average share price of $177.52 per share and the total transaction amounting to $2,307,760.00.
- On 4/12/2018 David Davidson, Insider, sold 3,000 with an average share price of $180.17 per share and the total transaction amounting to $540,510.00.
- On 4/2/2018 David Davidson, Insider, sold 22,000 with an average share price of $167.52 per share and the total transaction amounting to $3,685,440.00.
- On 3/15/2018 Mark Vachon, Director, sold 6,000 with an average share price of $214.38 per share and the total transaction amounting to $1,286,280.00.
- On 3/1/2018 Philip D Gregory, Insider, sold 2,250 with an average share price of $200.00 per share and the total transaction amounting to $450,000.00.
- On 2/2/2018 David Davidson, Insider, sold 4,000 with an average share price of $202.36 per share and the total transaction amounting to $809,440.00.
- On 1/30/2018 Jason Cole, Insider, sold 25,000 with an average share price of $195.91 per share and the total transaction amounting to $4,897,750.00.
Recent Trading Activity for NASDAQ:BLUE – bluebird bio (NASDAQ:BLUE)
Shares of NASDAQ:BLUE – bluebird bio closed the previous trading session at 177.35 up +1.65 0.94% with 175.27499389648438 shares trading hands.